ArticleWorld journal of surgical oncology2026
Prolonged S-adenosylmethionine exposure is associated with poorer treatment response and adverse outcomes in breast cancer: a retrospective cohort study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundHepatoprotective regimens are frequently used during chemotherapy for breast cancer, but their effects on oncologic outcomes remain unclear. S-adenosylmethionine (SAMe), a universal methyl donor, may influence treatment response through epigenetic and epitranscriptomic regulations.
methodsWe retrospectively analyzed data from 1013 consecutive women with primary breast cancer treated at Zhengzhou University People's Hospital between January 1, 2018 and January 1, 2020, and who underwent surgery followed by standard adjuvant chemotherapy. Overall survival (OS) and disease-free survival (DFS) were compared across hepatoprotective regimens. Propensity score matching (1:2) was performed to balance baseline characteristics between SAMe-treated and untreated patients. Receiver operating characteristic (ROC) analysis identified the optimal exposure threshold for recurrence discrimination, and survival was further assessed according to SAMe exposure duration using Cox proportional hazards models. Transcriptomic data from the Cancer Transcriptome Relationships Database (CTR-DB) were analyzed for SAMe-related pathways. In an exploratory neoadjuvant cohort (n = 62), intratumoral SAMe levels, m6A/m5C/m7G signals and METTL3/METTL14 expression were quantified in post-treatment tumor tissues.
resultsSAMe exposure during adjuvant chemotherapy was associated with shorter OS and DFS than other or no hepatoprotectants (both P < 0.05). After matching, prolonged SAMe exposure (≥ 14days) remained associated with worse OS and DFS than non-SAMe exposure (both P < 0.05), and this association persisted after multivariable adjustment. CTR-DB analyses revealed enrichment of methionine metabolism and RNA methylation-related pathways in non-responsive tumours. In the neoadjuvant cohort, tumours from patients with poor radiologic response showed higher intratumoral SAMe levels, stronger m6A signals, and higher METTL3 and METTL14 expression. Higher m6A levels were also associated with poorer MRI-based response.
conclusionsProlonged SAMe exposure during chemotherapy was associated with poorer treatment response and worse survival. Transcriptomic and tissue-level findings further support a possible link with altered m6A methylation. These results indicate that a cautious and standardized approach to SAMe use during chemotherapy may help limit treatment resistance and improve long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.